title: Addition of BMP-2 or BMP-6 to dexamethasone, ascorbic acid, and β-glycerophosphate may not enhance osteogenic differentiation of human periodontal ligament cells.
abstract: This study was designed to investigate the potential merits of the combined use of bone morphogenetic protein (BMP)-2 or BMP-6 and osteogenic supplements (OS) [dexamethasone, ascorbic acid (AA), and β-glycerophosphate] on osteogenic differentiation of periodontal ligament cells (PDLCs). Osteogenic differentiation was evaluated by quantitative alkaline phosphatase (ALP) assay, alizarin red staining, quantitative calcium assay, and the qRT-PCR analysis for the expression of collagen type I, runt-related transcription factor-2, osteopontin (OPN), and osteocalcin in PDLCs. Culture with BMP-2 or BMP-6+AA increased ALP activity of PDLCs, suggesting their osteo-inductive effects. However, longer duration of culture showed neither of the BMPs induced in vitro mineralization. In contrast, OS were able to increase ALP activity and OPN expressions, and also induced in vitro mineralization. The mineralization ability was not enhanced by the addition of BMP-2 or BMP-6. These findings suggest that the addition of BMP-2 or BMP-6 to OS may not enhance an osteogenic differentiation of hPDLCs.
authors.affiliation: Regea Institute for Regenerative Medicine, University of Tampere and Tampere University Hospital, Biokatu 12, 33520, Tampere, Finland. rashi.khanna-jain@regea.fi
authors.forename: Rashi
authors.initials: R
authors.lastname: Khanna-Jain
authors.forename: Hideki
authors.initials: H
authors.lastname: Agata
authors.forename: Annukka
authors.initials: A
authors.lastname: Vuorinen
authors.forename: George K B
authors.initials: GK
authors.lastname: Sándor
authors.forename: Riitta
authors.initials: R
authors.lastname: Suuronen
authors.forename: Susanna
authors.initials: S
authors.lastname: Miettinen
mesh_terms: D000469:Alkaline Phosphatase / Q000032:analysis; D000880:Anthraquinones / Q000032:analysis; D001205:Ascorbic Acid / Q000494:pharmacology; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D055418:Bone Morphogenetic Protein 6 / Q000494:pharmacology*; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000032:analysis; D002478:Cells, Cultured; D024042:Collagen Type I / Q000235:genetics; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics; D003907:Dexamethasone / Q000494:pharmacology; D005994:Glycerophosphates / Q000494:pharmacology; D006801:Humans; D015675:Osteocalcin / Q000235:genetics; D010012:Osteogenesis / Q000187:drug effects*; D053495:Osteopontin / Q000235:genetics; D010513:Periodontal Ligament / Q000166:cytology / Q000187:drug effects*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics
chemical_list: D000880:Anthraquinones; C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D055418:Bone Morphogenetic Protein 6; D024042:Collagen Type I; D050676:Core Binding Factor Alpha 2 Subunit; D005994:Glycerophosphates; D012333:RNA, Messenger; D015675:Osteocalcin; D053495:Osteopontin; C010078:alizarin; D003907:Dexamethasone; D000469:Alkaline Phosphatase; D001205:Ascorbic Acid; D002118:Calcium; C031463:beta-glycerophosphoric acid